Literature DB >> 35505770

Increased Lifetime Risk of Intestinal Complications and Extraintestinal Manifestations in Crohn's Disease and Ulcerative Colitis.

Gary R Lichtenstein1, Ahva Shahabi2, Seth A Seabury3, Darius N Lakdawalla4, Oliver Díaz Espinosa5, Sarah Green2, Michelle Brauer2, Robert N Baldassano6.   

Abstract

Patients with Crohn's disease (CD) or ulcerative colitis (UC) have high morbidity rates owing to debilitating intestinal complications and extraintestinal manifestations (EIMs). We retrospectively identified patients in the Truven MarketScan databases with an incident CD or UC diagnosis from January 2008 to September 2015 to quantify the incremental lifetime risk of experiencing an intestinal complication or EIM after CD or UC diagnosis. Seven intestinal complications and 13 categories of EIMs by site were identified, and lifetime risk of experiencing an intestinal complication or EIM from age at CD or UC diagnosis to end of life was estimated using parametric models. Results were compared with controls' propensity score matched by age, sex, health plan, and pre-index Charlson Comorbidity Index. The CD or UC incremental risk was calculated using the difference in rates between CD or UC patients and matched controls. A total of 34,692 CD patients and 48,196 UC patients with 1:1 matched controls were included. CD and UC patients had an increased lifetime risk of intestinal complications, which varied across ages, inflammatory bowel disease (IBD) types, and categories of intestinal complications and EIMs. CD and UC patients aged 0 to 11 years had the highest incremental lifetime risk for all 7 intestinal complications and the majority of EIMs, with blood EIMs associated with the highest incremental risk (CD: 32%; UC: 21%). CD and UC patients of all ages have a higher lifetime risk of experiencing intestinal complications and EIMs than patients without CD or UC. When evaluating the burden of disease on patients with IBD, it is important to include the burden of these intestinal complications and EIMs in the assessment.
Copyright © 2022, Gastro-Hep Communications, Inc.

Entities:  

Keywords:  Inflammatory bowel disease; comorbidities; extraintestinal manifestations; intestinal complications; lifetime disease burden

Year:  2022        PMID: 35505770      PMCID: PMC9053498     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  28 in total

1.  Incidence and risk of intestinal and extra-intestinal complications in Medicaid patients with inflammatory bowel disease: a 5-year population-based study.

Authors:  Gaurav Arora; Gurkirpal Singh; Shweta Vadhavkar; Shamita B Shah; Ajitha Mannalithara; Alka Mithal; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2010-04-29       Impact factor: 3.199

Review 2.  Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies.

Authors:  Tine Jess; Michael Gamborg; Pia Munkholm; Thorkild I A Sørensen
Journal:  Am J Gastroenterol       Date:  2007-03       Impact factor: 10.864

Review 3.  Extraintestinal manifestations of inflammatory bowel disease.

Authors:  S Ardizzone; P Sarzi Puttini; A Cassinotti; G Bianchi Porro
Journal:  Dig Liver Dis       Date:  2008-07       Impact factor: 4.088

4.  Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort.

Authors:  Lori A Ashworth; Amy Billett; Paul Mitchell; Federica Nuti; Corey Siegel; Athos Bousvaros
Journal:  Inflamm Bowel Dis       Date:  2011-09-01       Impact factor: 5.325

5.  Lifetime Economic Burden of Crohn's Disease and Ulcerative Colitis by Age at Diagnosis.

Authors:  Gary R Lichtenstein; Ahva Shahabi; Seth A Seabury; Darius N Lakdawalla; Oliver Díaz Espinosa; Sarah Green; Michelle Brauer; Robert N Baldassano
Journal:  Clin Gastroenterol Hepatol       Date:  2019-07-18       Impact factor: 11.382

Review 6.  Reduction of colorectal cancer risk in patients with Crohn's disease.

Authors:  Gary R Lichtenstein
Journal:  Rev Gastroenterol Disord       Date:  2002

7.  Total and cancer mortality in a cohort of ulcerative colitis and Crohn's disease patients: The Florence inflammatory bowel disease study, 1978-2010.

Authors:  Saverio Caini; Siro Bagnoli; Domenico Palli; Calogero Saieva; Marco Ceroti; Benedetta Bendinelli; Melania Assedi; Giovanna Masala
Journal:  Dig Liver Dis       Date:  2016-07-15       Impact factor: 4.088

8.  Natural history of pediatric Crohn's disease: a population-based cohort study.

Authors:  Gwenola Vernier-Massouille; Mamadou Balde; Julia Salleron; Dominique Turck; Jean Louis Dupas; Olivier Mouterde; Véronique Merle; Jean Louis Salomez; Julien Branche; Raymond Marti; Eric Lerebours; Antoine Cortot; Corinne Gower-Rousseau; Jean Frédéric Colombel
Journal:  Gastroenterology       Date:  2008-07-03       Impact factor: 22.682

9.  The direct and indirect cost burden of Crohn's disease and ulcerative colitis.

Authors:  Teresa B Gibson; Eliza Ng; Ronald J Ozminkowski; Shaohung Wang; Wayne N Burton; Ron Z Goetzel; Ross Maclean
Journal:  J Occup Environ Med       Date:  2008-11       Impact factor: 2.162

Review 10.  Emerging treatment options for extraintestinal manifestations in IBD.

Authors:  Thomas Greuter; Florian Rieder; Torsten Kucharzik; Laurent Peyrin-Biroulet; Alain M Schoepfer; David T Rubin; Stephan R Vavricka
Journal:  Gut       Date:  2020-08-26       Impact factor: 31.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.